Day two of Pfizer's first-quarter print holds the capital-allocation line that made it news on day one. Revenue came in at $14.5 billion, up 5% year-over-year. Adjusted diluted EPS was $0.75, down 18% from $0.92 a year ago, on a reported $0.47 per share. Pfizer reaffirmed full-year guidance: $59.5 to $62.5 billion in revenue, $2.80 to $3.00 in adjusted EPS. The line that travelled is the buyback line. "No share repurchases have been completed to date in 2026," the release reads. The remaining authorization is $3.3 billion. Guidance does not anticipate any 2026 repurchases. [1] The paper's May 6 standard on the zero-buybacks position named it the most aggressive disciplined-cohort line in pharma.

Padcev was the operational bright spot. The Seagen-acquired antibody-drug conjugate grew 39% operationally, driven by first-line market share in metastatic urothelial cancer and the cisplatin-ineligible MIBC indication. [2] BMO's Evan Seigerman pressed CFO Dave Denton on the buyback freeze; Denton said the lever would "come back into greater consideration" as cash flow improves post-LOE. [3]

The other Day-2 read: VYNDAQEL exclusivity extended to mid-2031 via patent settlement adds 2.5 years of post-2028 cover, which is what lets the disciplined-cohort posture hold without reactivating buybacks now. [4]

-- THEO KAPLAN, San Francisco